Multiple studies have indicated that instances of CD19-negative relapses occur in approximately 9% to 25% of cases of B-cell acute lymphoblastic leukemia treated with CAR T cell therapy (31). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.